AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32986265
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy (6 months of intradialytic exercise)
Trial: 34602438
Drug: Femitex‐SP4 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Femitex‐SP4 (500 mg powdered herbs in capsule form, twice daily)
Trial: 32690739
Drug: Oropharyngeal surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oropharyngeal surfactant (120 mg vial for <26 weeks GA; 240 mg vial for 26-28 +6 weeks GA) in addition to CPAP
Trial: 35569763
Drug: Intravitreal 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal 1.0 mg risuteganib
Trial: 34062418
Drug: Metformin 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 3 × 500 mg (group A)
Trial: 34062418
Drug: Metformin 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 3 × 1000 mg (group B)
Trial: 32022282
Drug: US-approved reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US-approved reference biologics
Trial: 32022282
Drug: EU-approved reference
RxNorm normalized name: chlorine dioxide
DrugBank: Chlorine dioxide (DB12453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EU-approved reference biologics
Trial: 35124703
Drug: Adjuvant capecitabine-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant capecitabine-containing chemotherapy (TX + CEX: capecitabine-docetaxel, followed by cyclophosphamide-epirubicin-capecitabine)
Trial: 35124703
Drug: Conventional chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy (T + CEF: docetaxel, followed by cyclophosphamide-epirubicin-fluorouracil)
Trial: 33813084
Drug: Adrenomedullin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenomedullin (30 μg/kg for 7 days)
Trial: 33813084
Drug: Adrenomedullin (56
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenomedullin (56 μg/kg for 7 days)
Trial: 34422246
Drug: Fast inhalation
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast inhalation and slow exhalation (A) group
Trial: 32133329
Drug: Nusinersen treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nusinersen treatment
Trial: 32027167
Drug: GP40061 insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP40061 insulin glargine (GP‐Gla)
Trial: 33660798
Drug: Pembrolizumab (alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (alone or in combination with chemotherapy)
Trial: 33660798
Drug: Pembrolizumab combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab combined with chemotherapy
Trial: 33725327
Drug: Standard low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard low-dose protocol stereoradiography
Trial: 35122746
Drug: Mindfulness-Based Stress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-Based Stress Reduction (MBSR) for 6 weeks, 1 hour daily sessions
Trial: 35431355
Drug: Nonsurgical periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonsurgical periodontal therapy
Trial: 33998255
Drug: 0/1-hour unmasked
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0/1-hour unmasked hs-cTnT protocol (reported to <5 ng/L)
Trial: 33998255
Drug: 0/3-hour masked
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0/3-hour masked hs-cTnT protocol (reported to ≤29 ng/L)
Trial: 33998255
Drug: 0/1-hour unmasked
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0/1-hour unmasked hs-cTnT protocol (reported to <5 ng/L) among participants with initial troponin T concentrations ≤29 ng/L
Trial: 33998255
Drug: 0/3-hour masked
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0/3-hour masked hs-cTnT protocol (reported to ≤29 ng/L) among participants with initial troponin T concentrations ≤29 ng/L
Trial: 33578226
Drug: Enoxaparin 20
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 20 mg twice a day starting 24 h after onset of ICH
Trial: 32976660
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg piroxicam
Trial: 34495988
Drug: ChAd63 CAT
RxNorm normalized name: Spotted cat
DrugBank: Channel catfish (DB15548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAd63 CAT vaccine (three-antigen: CSP, AMA1, ME-TRAP)
Trial: 34495988
Drug: ChAd63 CA
RxNorm normalized name: Ca 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAd63 CA vaccine (two-antigen: CSP, AMA1)
Trial: 35168962
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of desmopressin and VWF-containing concentrate
Trial: 35168962
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of desmopressin and VWF-containing concentrate (medical procedures)
Trial: 35588887
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg oral twice a day for three days before CPB
Trial: 34937388
Drug: Evacetrapib (130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evacetrapib (130 mg); placebo-adjusted percent increase in apoA1 in HDL that contains apoC3: 99%.
Trial: 34937388
Drug: Torcetrapib (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torcetrapib (60 mg); placebo-adjusted percent increase in apoA1 in HDL that contains apoC3: 50%.
Trial: 34937388
Drug: Both CETP
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both CETP inhibitors; increase in apoA1 in HDL that contains apoC1: 71% (evacetrapib) and 40% (torcetrapib).
Trial: 34937388
Drug: Both CETP
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both CETP inhibitors; no response in HDL that contains apoL1.
Trial: 32514702
Drug: Medial midpatellar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medial midpatellar (MMP) injection of hyaluronic acid (HA)
Trial: 32514702
Drug: Anteromedial (AM)
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anteromedial (AM) injection of hyaluronic acid (HA)
Trial: 33970454
Drug: Salvage chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvage chemotherapy
Trial: 32162241
Drug: WP-MND (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WP-MND (1 or 2 servings daily, 21 g protein, 3 g leucine, 10 µg vitD, 500 mg calcium per serving)
Trial: 32162241
Drug: WP-MND (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WP-MND (1 or 2 servings daily) during OLE
Trial: 32833890
Drug: Maintenance dose
RxNorm normalized name: Firmagon 80mg Powder for Injection Maintenance Dose Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance dose of 1.2 g·d‐1 Beta-Alanine
Trial: 34656202
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Couple Therapy (CBCT)
Trial: 34656202
Drug: Topical Lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Lidocaine
Trial: 35864302
Drug: Betahistine dimesylate
RxNorm normalized name: betahistine dimesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine dimesylate 12 mg
Trial: 36763929
Drug: Escitalopram treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram treatment
Trial: 35986348
Drug: Prisma intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prisma intervention (psychoeducational group intervention) consisting of four weekly group sessions.
Trial: 34281376
Drug: Baseline glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline glucose <150 mg/dL
Trial: 34281376
Drug: Elevated baseline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated baseline serum glucose ?150 mg/dL
Trial: 37526748
Drug: Treatment arm
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment arm
Trial: 32306953
Drug: High risk
RxNorm normalized name: Hep B, adolescent/high risk infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High risk basic (HRB) group - basic prevention regimen including oral-hygiene instruction, hands-on brushing practice, supervised daytime tooth brushing, sealant application, provision of toothbrush, fluoride-containing dentifrice, and a guidebook.
Trial: 33386796
Drug: Intravenous nicorandil
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nicorandil infusion before balloon dilation or stent placement
Trial: 33386796
Drug: Intravenous nicorandil
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nicorandil infusion
Trial: 32195722
Drug: Oral nutrition
RxNorm normalized name: BAGS/TUBES/SUPPLIES FOR ORAL NUTRITION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutrition supplement containing collagen peptides (10.0 g, once-a-day)
Trial: 35354530
Drug: Novel soaking
RxNorm normalized name: magnesium sulfate
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Novel soaking solution (dexamethasone, gentamicin, and vitamin B12), soaked for 15 minutes, three times a day for four weeks.
Trial: 34789181
Drug: Medication+tDCS (n=15,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication+tDCS (n=15, receiving medications plus tDCS with 2 mA intensity over dorsolateral prefrontal cortex for 10 days, two sessions per day each for 20 min)
Trial: 34789181
Drug: Medication (n=15,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (n=15, receiving mood stabilizers including 2-5 tables of 300 mg lithium, 200 mg sodium valproate, and 200 mg carbamazepine two times per day)
Trial: 34789181
Drug: Medication+tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication+tDCS
Trial: 35213714
Drug: GLWL‐01 (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLWL‐01 (450 mg twice daily)
Trial: 34626318
Drug: Anticoagulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation therapy
Trial: 32320767
Drug: Pivotal trials
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivotal trials for systemic therapies for plaque psoriasis
Trial: 34910203
Drug: filgotinib 200
RxNorm normalized name: nilotinib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: filgotinib 200 mg plus MTX
Trial: 34910203
Drug: filgotinib 100
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: filgotinib 100 mg plus MTX
Trial: 35263963
Drug: filgotinib 200
RxNorm normalized name: nilotinib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: filgotinib 200 mg
Trial: 32487336
Drug: Azithromycin (AZT)
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin (AZT) plus Echinacea (5 ml oral suspension, 3 times daily for 10 consecutive days every month for 6 months)
Trial: 32487336
Drug: Azithromycin (AZT)
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin (AZT) (60 mg/kg divided as 10 mg/kg/day over 6 consecutive days every month for 6 months)
Trial: 36244779
Drug: Dexmedetomidine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.2 to 0.7 µg/kg/h, DEX group)
Trial: 33764851
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g soy protein (∼24–26/day genistein; ∼40–43/day total isoflavones)
Trial: 36633795
Drug: Fractional picosecond
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional picosecond 1064 nm Nd: YAG laser (FxPico) treatment
Trial: 32464321
Drug: No Aspirin
RxNorm normalized name: XS No Aspirin PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Aspirin (Control)
Trial: 34073918
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BoNT‐A) injection
Trial: 36443490
Drug: α-lactalbumin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-lactalbumin (40 g)
Trial: 33559440
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with conventional visual stimulation therapy
Trial: 33559440
Drug: Conventional visual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional visual stimulation therapy
Trial: 35393316
Drug: Supervised acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised acute physical exercise therapy prior to immune-chemotherapy infusion
Trial: 32827458
Drug: Multifaceted intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifaceted intervention for intensive BP treatment including protocol‐based treatment using the SPRINT intensive BP management algorithm, dissemination of SPRINT findings, BP audit and feedback, home BP monitoring, and health coaching.
Trial: 32827458
Drug: Multifaceted intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifaceted intervention for intensive BP treatment
Trial: 35238969
Drug: Ultra-low-dose (ULD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low-dose (ULD) CT
Trial: 35238969
Drug: Standard-dose (SD)
RxNorm normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose (SD) CT
Trial: 37784098
Drug: Immediate antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate antibiotic prescription (IAP)
Trial: 37784098
Drug: Delayed antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed antibiotic prescription (DAP)
Trial: 37784098
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic prescription (NAP)
Trial: 33301246
Drug: BNT162b2 vaccine
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 vaccine (30 μg per dose, two doses, 21 days apart)
Trial: 38438427
Drug: BNT162b2 vaccine
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 vaccine
Trial: 35279718
Drug: EV 2
RxNorm normalized name: Padcev 20 MG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV 2 mg + DNG 2-3 mg
Trial: 35279718
Drug: EE 0.03
RxNorm normalized name: EE 0.03MG/LEVONORG 0.15MG TAB,28
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE 0.03 mg + DNG 2 mg
Trial: 35279718
Drug: DNG 2
RxNorm normalized name: Desogestrel
DrugBank: Desogestrel (DB00304)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DNG 2 mg
Trial: 32852904
Drug: Mepivacaine (52.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepivacaine (52.5 mg)
Trial: 32852904
Drug: Hyperbaric Bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric Bupivacaine (11.25 mg)
Trial: 32852904
Drug: Isobaric Bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isobaric Bupivacaine (12.5 mg)
Trial: 33534231
Drug: Biological mesh
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological mesh closure
Trial: 35725632
Drug: 24% oral
RxNorm normalized name: Entero VU, 24% oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24% oral sucrose
Trial: 35791269
Drug: Baseline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline plus treatment model in a German EMS and health care system
Trial: 33858875
Drug: eHealth programme
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eHealth programme comprising balance exercise, cognitive‐motor exercise and cognitive‐behavioural therapy
Trial: 35134697
Drug: Pomegranate supplement
RxNorm normalized name: Pomegranate
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate supplement for 4 weeks
Trial: 33950030
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral conjugated equine estrogen (CEE) (0.625 mg) plus medroxyprogesterone acetate (2.5 mg) for women with a uterus (5.7 years)
Trial: 33950030
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral CEE (0.625 mg) alone for women with a hysterectomy (7.2 years)
Trial: 33836826
Drug: Ivermectin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (300 mcg/kg) administered daily for three consecutive days
Trial: 33836826
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered daily for three consecutive days
Trial: 32176305
Drug: Smoking cigarettes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking cigarettes monthly or less
Trial: 32176305
Drug: Smoking cigarettes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking cigarettes daily
Trial: 35416163
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (anterior‐superior RCT type 1,2,3 or combination)
Trial: 35416163
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (posterior‐superior RCT type 3, 4, 5 or combination)
Trial: 35791906
Drug: Daily co-use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily co-use of alcohol and cannabis
Trial: 34668237
Drug: Hair lotion
RxNorm normalized name: cat hair extract
DrugBank: Felis catus hair (DB10499)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hair lotion containing creatine, acetyl tetrapeptide‐2 and B vitamins with mild shampoo
Trial: 32672584
Drug: Topical travoprost
RxNorm normalized name: Travoprost
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Topical travoprost (once-daily)
Trial: 32883333
Drug: Hydrocortisone (HC)
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone (HC) 0.5 mg/kg twice a day for 7 days, then 0.5 mg/kg once a day for 3 days
Trial: 34790015
Drug: nucleos(t)ide analog
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nucleos(t)ide analog (NUC)-based therapy
Trial: 36496154
Drug: Tailored physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored physical therapy program (Enhanced PT)
Trial: 36496154
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy for chronic pain (if re-randomized)
Trial: 36496154
Drug: Spinal manipulation
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal manipulation therapy (if re-randomized)
Trial: 33558351
Drug: SISU software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SISU software agent-based intervention, delivered over 3 consecutive days, based on therapeutic writing and acceptance and commitment therapy principles.
Trial: 33558351
Drug: SISU software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SISU software agent-based intervention
Trial: 35734648
Drug: Pre-operative antibiotics
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative antibiotics (intravenous cefazolin 2-g)
Trial: 32468765
Drug: No pre-operative
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No pre-operative antibiotics
Trial: 33045448
Drug: Transvaginal ovarian
RxNorm normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transvaginal ovarian needle puncture prior to induction with aromatase inhibitors and gonadotropins
Trial: 33045448
Drug: Induction using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction using aromatase inhibitors (Letrozol 2.5 mg twice daily for 5 days) and FSH (75 IU daily from cycle day 3)
Trial: 33736523
Drug: Statin prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin prescription in HIV-negative patients
Trial: 33736523
Drug: Statin prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin prescription in HIV-positive patients
Trial: 33736523
Drug: Aspirin prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin prescription in HIV-negative patients
Trial: 33736523
Drug: Aspirin prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin prescription in HIV-positive patients
Trial: 34209080
Drug: Pelvic floor
RxNorm normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic floor muscle training (PFMT) - supervised exercise twice a week for 12 weeks
Trial: 32686119
Drug: Hand‐Arm Bimanual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hand‐Arm Bimanual Intensive Therapy (HABIT) (90 hours)
Trial: 34908536
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate (20 mg/kg)